HIGHLIGHTS
- who: Ye Chen and Xingchen Peng from the West China Hospital, Sichuan University, Chengdu, China, West China School of Medicine, West China Hospital, Sichuan have published the paper: Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma, in the Journal: (JOURNAL)
- what: For the DSA, a one-way sensitivity analysis was conducted to examine the impact of utility and cost parameters on the ICER. The study demonstrated that avelumab maintenance therapy was a cost-effective first-line treatment compared with BSC in patients . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.